Sofe-M is named as an intervention in 2 current clinical trials in our USA, France, Spain, Italy, Japan, South Korea, Australia, Ireland, UK, China, Germany, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Taiwan and Singapore registers. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Eli Lilly and Company. The most-studied condition is Ovarian Neoplasms.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
NCT07213804 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms
|
Phase 3 | Recruiting | Eli Lilly and Company | Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia |
|
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
NCT06400472 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms
|
Phase 1 | Recruiting | Eli Lilly and Company | USA, France, Spain, Italy, Japan, South Korea, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Eli Lilly and Company | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our USA, France, Spain, Italy, Japan, South Korea, Australia, Ireland, UK, China, Germany, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Taiwan and Singapore registers name Sofe-M (also registered as LY4170156) as a drug or biological intervention, as of the registry sync on 1 October 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in USA, 2 with sites in France, 2 with sites in Spain, 2 with sites in Italy, 2 with sites in Japan, 2 with sites in South Korea, 2 with sites in Australia, 1 with sites in Ireland, 1 with sites in UK, 1 with sites in China, 1 with sites in Germany, 1 with sites in Netherlands, 1 with sites in Belgium, 1 with sites in Denmark, 1 with sites in Poland, 1 with sites in Switzerland, 1 with sites in Austria, 1 with sites in Czechia, 1 with sites in Norway, 1 with sites in Canada, 1 with sites in Brazil, 1 with sites in Mexico, 1 with sites in Taiwan and 1 with sites in Singapore. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
The lead sponsor is Eli Lilly and Company. The number in brackets is how many trials each organisation leads.
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sofe-M works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sofe-M works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sofe-M (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 1 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.